Ongoing Trials Looking at Combinations in Bladder Cancer

Video

Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

Arjun V. Balar, MD, assistant professor in the Department of Medicine and director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

According to Balar, CTLA-4 blockade is being tested in combination with PD-1 blockade. The PD-1 pathway can play an important role in the treatment of bladder cancer, but it still needs to be tested further. This strategy is being investigated in both the CheckMate901 trial and the DANUBE trial.

Recent Videos
Related Content
FDA Grants Approval to Durvalumab in MIBC

FDA Grants Approval to Durvalumab in MIBC

Jordyn Sava
March 28th 2025
Article

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.

Read More

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC

Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC

Jordyn Sava
March 26th 2025
Article

Belzupacap sarotalocan showed rapid immune activation and a favorable safety profile as a treatment for non–muscle-invasive bladder cancer.

Read More

Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

Jonah Feldman
March 24th 2025
Article

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

Read More

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More